Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora Sells 15,000 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora sold 15,000 shares of the stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $6.32, for a total transaction of $94,800.00. Following the completion of the transaction, the chief financial officer now owns 1,426,506 shares of the company’s stock, valued at approximately $9,015,517.92. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Michael Secora also recently made the following trade(s):

• On Tuesday, September 10th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.17, for a total transaction of $92,550.00.
• On Tuesday, August 13th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.35, for a total transaction of $95,250.00.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $6.18 on Friday. The company has a 50 day moving average price of $6.70 and a 200-day moving average price of $7.93. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.97 and a 52 week high of $15.74. The firm has a market capitalization of $1.47 billion, a PE ratio of -3.86 and a beta of 0.80. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. During the same quarter in the prior year, the firm earned ($0.38) earnings per share. The business’s revenue was up 30.9% compared to the same quarter last year. As a group, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Institutional Trading of Recursion Pharmaceuticals

A number of large investors have recently made changes to their positions in RXRX. Exchange Traded Concepts LLC boosted its holdings in shares of Recursion Pharmaceuticals by 24.9% in the third quarter. Exchange Traded Concepts LLC now owns 25,182 shares of the company’s stock worth $166,000 after buying an additional 5,021 shares during the last quarter. San Luis Wealth Advisors LLC purchased a new position in shares of Recursion Pharmaceuticals in the third quarter worth approximately $69,000. Green Alpha Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 2.9% in the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock worth $427,000 after buying an additional 1,800 shares during the last quarter. Handelsbanken Fonder AB boosted its holdings in shares of Recursion Pharmaceuticals by 33.4% in the third quarter. Handelsbanken Fonder AB now owns 69,500 shares of the company’s stock worth $458,000 after buying an additional 17,400 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Recursion Pharmaceuticals by 249.0% during the third quarter. SG Americas Securities LLC now owns 89,325 shares of the company’s stock valued at $589,000 after purchasing an additional 63,727 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on RXRX shares. Leerink Partners reduced their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Needham & Company LLC reduced their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. KeyCorp reduced their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.